Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: RXGOLF who wrote (20824)	5/14/1998 10:04:00 PM
From: Torben Noerup Nielsen	Read Replies (1) \| Respond to of 32384

Greg, Stepping back from the LGND trenches for a moment, the best thing that can happen is for a very large number of new cancer drugs to be approved. Approval seems to be nothing much more than a licence to conduct a real experiment where the MDs can choose freely who to treat with which drug. And they can treat during the earlier stages when the disease may be controllable or even curable. As a result of such widespread ''testing", we will accumulate more knowledge about what works and what doesn't. My personal feeling is that the next 5 years or so could see cancer become at least a manageable disease. I sincerely hope that it will not be much longer than that before current radiation and chemotherapy treatments are a thing of the past. Now, it is not clear what share of the pie LGND will eventually have. They could end up being more or less excluded from it. What makes that less likely is the large patent estate they are accumulating and also the fact that it is not just cancer they work on. That is, there is the metabolic disease as well. And I still think it would be neat if they could take a technology like the one they are getting from SRGN and adapt it for use as an antibiotic. Ought to be workable..... Thanks, Torben

To: RXGOLF who wrote (20824)	5/14/1998 10:23:00 PM
From: Machaon	Respond to of 32384

Greg, what are your feelings about discussing future earnings, when it comes to biotechs? Should we not even be discussing the projections? Without factoring in possible future earnings, for a biotech, is it still possible to evaluate a biotech's current and future value? It's an interesting idea. A new way to value biotechs, without regard to future earnings. Ahhhhh, the smell of smoke, coming from certain brains, being used beyond their capacities! <g> Regards, Bob